Latest News and Press Releases
Want to stay updated on the latest news?
-
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
-
NodThera Ltd (“NodThera” or the “Company”) Aberrant NLRP3 activation is recognised as a critical driver of cardiometabolic diseaseA Phase Ib/IIa trial of lead candidate NT-0796 will assess...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor NT-0796 demonstrates...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors Oral, small molecule, clinical candidates NT-0249...
-
NodThera Ltd(“NodThera” or the “Company”) NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening...
-
NodThera Ltd(“NodThera” or the “Company”) NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening...
-
NodThera(“NodThera” or the “Company”) NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer Dr Keeney joins NodThera with over 20 years of...
-
NodThera(“NodThera” or the “Company”) NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer Dr Keeney joins NodThera with over 20 years of...
-
NodThera(“NodThera” or the “Company”) NodThera secures £28 million ($40 million) Series A Financing NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment...